SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michail Shadkin who started this subject6/28/2001 5:18:31 PM
From: xaver17   of 6873
 
TARO - excerpt from TheStreet.com (Herb Greenberg)

Then there's Taro, a maker of generic drugs, whose stock trades at nearly 10-times sales. Much of the rise occurred after the company received FDA approval for a generic version of Schering-Plough's Lotrisone antifungal cream. But then E. Fougera & Co., a private company, received approval a week later, and it is undercutting Taro's price. (Gotta watch whenever a private company competes with a public company; the public company gets all the press and investors tend to gloss over the private competitor. That can often be a costly mistake. But, hey, we're talking about an Israeli-based generic-drug maker that doesn't file financials on the SEC's EDGAR system. The stocks of these generic-drug companies, they have a mind of their own, I tell ya', a mind of their own! Oh, and did I tell you that Taro announced Thursday morning it's splitting its stock 2 for 1? I guess we're back to that phase of the market again!)

thestreet.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News